Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALAGet Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on the stock. LADENBURG THALM/SH SH reduced their price target on shares of Calithera Biosciences from $3.00 to $1.50 in a research report on Wednesday. SVB Leerink reduced their price target on shares of Calithera Biosciences from $3.00 to $2.00 and set an “outperform” rating for the company in a research report on Monday, April 4th. Finally, Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Calithera Biosciences has an average rating of “Hold” and an average target price of $2.00.

Shares of NASDAQ:CALA opened at $0.16 on Thursday. Calithera Biosciences has a fifty-two week low of $0.16 and a fifty-two week high of $2.59. The business has a 50-day simple moving average of $0.38 and a two-hundred day simple moving average of $0.64. The firm has a market cap of $12.59 million, a price-to-earnings ratio of -0.10 and a beta of 1.64.

Calithera Biosciences (NASDAQ:CALAGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). During the same quarter in the previous year, the business posted ($0.28) EPS. As a group, sell-side analysts anticipate that Calithera Biosciences will post -0.62 EPS for the current year.

Several large investors have recently made changes to their positions in CALA. Acadian Asset Management LLC boosted its stake in Calithera Biosciences by 1,090.8% in the 4th quarter. Acadian Asset Management LLC now owns 1,856,730 shares of the biotechnology company’s stock worth $1,234,000 after purchasing an additional 1,700,803 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in Calithera Biosciences by 2,823.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,518,553 shares of the biotechnology company’s stock worth $1,010,000 after purchasing an additional 1,466,611 shares during the period. Morgan Stanley boosted its stake in Calithera Biosciences by 288,904.1% in the 2nd quarter. Morgan Stanley now owns 985,504 shares of the biotechnology company’s stock worth $2,060,000 after purchasing an additional 985,163 shares during the period. Renaissance Technologies LLC boosted its stake in Calithera Biosciences by 258.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,357,400 shares of the biotechnology company’s stock worth $903,000 after purchasing an additional 978,800 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in Calithera Biosciences by 386.2% in the 3rd quarter. GSA Capital Partners LLP now owns 525,667 shares of the biotechnology company’s stock worth $1,146,000 after purchasing an additional 417,556 shares during the period. Institutional investors own 55.84% of the company’s stock.

About Calithera Biosciences (Get Rating)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.

See Also

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.